Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to learn about the Effects of neoadjuvant therapy with carboplatin, paclitaxel combined with anti-PD-1 drugs on cognitive function in patients with resectable head and neck squamous cell carcinoma: a prospective cohort study
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Neoadjuvant therapy+ Surgery group( Group A) | The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), untreated, and planned to undergo surgical treatment + combined chemotherapy and immunotherapy. |
| |
| Direct surgery group (Group B) | The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), untreated, and planned to undergo surgery. |
| |
| Healthy people (Group C) | Healthy people |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Carboplatin（ neoadjuvant） | Drug | Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle |
|
| Measure | Description | Time Frame |
|---|---|---|
| cognitive adverse events, CoAE | Scores on two or more of the neuropsychological battery tests (NBT) of the HVLT-R, COWA, and TMT are 1.5 SD below the standard mean (or the mean score of an appropriate control group), Or a single test score that is 2.0 SD below the mean can be marked as an objective cognitive adverse event (CoAE). | Baseline, 9 weeks, 6 months, 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Major pathological response rate | Defined as the proportion of subjects with ≤10% viable tumor cells in resection specimens to total subjects | Within 30 days after surgery |
| Montreal Cognitive Assessment, MoCA |
Not provided
Inclusion Criteria:
1: The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), without treatment, and planned to undergo only surgical treatment or surgical treatment + chemotherapy and immunotherapy.
2: Can speak Chinese and have certain reading and writing skills
3: Healthy group: Dental inpatients with non-oral cancer, no history of neurological diseases, and no previous history of malignant tumors
Exclusion Criteria:
1: Brain tumor, brain injury, or stroke at baseline or during follow-up
2: A history of stroke or a medical condition that puts you at high risk for future dementia or recurrence
3: Active mental illness or active narcotic drug use, including using alcohol more than 4 times per day or more than 4 times per week
4: Neurocognitive diseases that affect cognitive function, such as Parkinson's disease or Alzheimer's disease
5: History of drug-associated encephalopathy or brain infection
6: Patients who change their treatment plan during treatment
7: Patients who are currently taking or have taken antidepressants
Not provided
Not provided
Not provided
The patients were diagnosed with head and neck squamous cell carcinoma (stages I-IV) and did not receive treatment. They planned to receive only surgical treatment or combined surgical treatment + chemotherapy and immunotherapy. They were divided into two groups, and the participating groups were selected according to the inclusion criteria.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | Guanzhou | Guangdong | 510000 | China |
Not provided
Not provided
Not provided
Not provided
| Paclitaxel （neoadjuvant） | Drug | Paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle |
|
| Anti-PD-1 Drugs | Drug | Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle |
|
| Surgical resection | Procedure | Standard of care |
|
Baseline, 9 weeks, 6 months, 12 months
| The total score is obtained by adding up the scores of each item, and the full score is 30 points. The application results of the original English version of the scale designer show that if the number of years of education is ≤12 years, 1 point is added, |
| perceived cognitive decline events , PCDE | Baseline, 9 weeks, 6 months, 12 months | 1/2 standard deviation (SD) of the PCI score in the baseline healthy population is defined as a minimal clinically important difference (MCID), and a change in PCI score that exceeds the MCID in each test will be labeled as PCDE. |
| complete pathological response rate | Defined as the proportion of subjects without viable tumor cells in the resection specimen to the total subjects | Within 30 days after surgery |
| ID | Term |
|---|---|
| D000077195 | Squamous Cell Carcinoma of Head and Neck |
| ID | Term |
|---|---|
| D002294 | Carcinoma, Squamous Cell |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006258 | Head and Neck Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided